Zura Bio (NASDAQ:ZURA) Earns Neutral Rating from Analysts at HC Wainwright

HC Wainwright initiated coverage on shares of Zura Bio (NASDAQ:ZURA) in a report issued on Thursday morning, MarketBeat.com reports. The firm issued a neutral rating and a $5.00 price target on the stock.

A number of other research firms have also issued reports on ZURA. Cantor Fitzgerald restated an overweight rating on shares of Zura Bio in a research report on Thursday, August 15th. Oppenheimer upped their price target on shares of Zura Bio from $16.00 to $21.00 and gave the company an outperform rating in a report on Friday, May 10th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of Moderate Buy and a consensus target price of $15.50.

Zura Bio Trading Down 4.0 %

Zura Bio stock opened at $3.62 on Thursday. The firm’s 50-day simple moving average is $3.69 and its 200 day simple moving average is $3.77. Zura Bio has a 52 week low of $2.00 and a 52 week high of $7.22.

Zura Bio (NASDAQ:ZURA) last released its earnings results on Tuesday, August 13th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.02). As a group, sell-side analysts predict that Zura Bio will post -0.53 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Someit Sidhu sold 51,728 shares of the firm’s stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $3.87, for a total transaction of $200,187.36. Following the completion of the transaction, the director now owns 2,085,418 shares in the company, valued at approximately $8,070,567.66. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 15.80% of the stock is currently owned by insiders.

Institutional Trading of Zura Bio

Several hedge funds have recently modified their holdings of the stock. Renaissance Technologies LLC raised its position in shares of Zura Bio by 51.3% during the 2nd quarter. Renaissance Technologies LLC now owns 17,400 shares of the company’s stock valued at $61,000 after acquiring an additional 5,900 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Zura Bio by 15.8% in the second quarter. Bank of New York Mellon Corp now owns 47,109 shares of the company’s stock valued at $165,000 after buying an additional 6,412 shares during the period. Forefront Analytics LLC increased its holdings in Zura Bio by 46.8% during the 4th quarter. Forefront Analytics LLC now owns 21,229 shares of the company’s stock worth $99,000 after purchasing an additional 6,765 shares in the last quarter. AQR Capital Management LLC bought a new position in shares of Zura Bio during the second quarter worth about $43,000. Finally, Armistice Capital LLC grew its stake in shares of Zura Bio by 15.4% during the 4th quarter. Armistice Capital LLC now owns 1,824,000 shares of the company’s stock worth $8,518,000 after acquiring an additional 244,000 shares in the last quarter. 61.14% of the stock is owned by institutional investors.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.